Ciprofloxacin otic solution - SALVAT

Drug Profile

Ciprofloxacin otic solution - SALVAT

Alternative Names: 0.2% Ciprofloxacin otic solution - SALVAT; CETRAXAL; DF-289; InfectoCipro; Ototopical ciprofloxacin; Unicexal

Latest Information Update: 31 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SALVAT
  • Class Antibacterials; Cyclopropanes; Fluoroquinolones; Piperazines; Small molecules
  • Mechanism of Action DNA topoisomerase IV inhibitors; Type II bacterial DNA topoisomerase inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Otitis externa
  • No development reported Otitis media

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 31 Aug 2015 No development reported - Phase-III for Otitis media (In children) in Spain, Denmark, Finland and Sweden (Otic)
  • 01 Jun 2013 SALVAT completes a phase III trial in Otitis media (in children) in Denmark, Finland, Spain and Sweden (NCT01404611)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top